Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Cancer biomarker HER-2/neu in breast cancer in Indian women

Authors Singhai R, Patil VW, Patil AV

Published 29 March 2011 Volume 2011:3 Pages 21—26


Review by Single-blind

Peer reviewer comments 3

This paper has been retracted.
Rajeev Singhai1, Amit V Patil2, Vinayak W Patil1
Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, India

Aim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.
Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.
Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.
Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.

Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

The p53 breast cancer tissue biomarker in Indian women

Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Breast Cancer: Targets and Therapy 2011, 3:71-78

Published Date: 11 August 2011

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Breast Cancer: Targets and Therapy 2011, 3:27-33

Published Date: 19 April 2011

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Breast Cancer: Targets and Therapy 2011, 3:9-19

Published Date: 16 March 2011

Readers of this article also read:

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Redondo A, Martínez V, Zamora P, Castelo B, Pinto A, Cruz P, Higuera O, Mendiola M, Hardisson D, Espinosa E

OncoTargets and Therapy 2014, 7:2175-2181

Published Date: 27 November 2014

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkær-Jensen S

Breast Cancer: Targets and Therapy 2014, 6:179-189

Published Date: 27 November 2014

miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer

Fesler A, Zhai H, Ju J

OncoTargets and Therapy 2014, 7:1481-1485

Published Date: 21 August 2014

“Denervation” of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome

Hohenforst-Schmidt W, Zarogoulidis P, Oezkan F, Mahnkopf C, Grabenbauer G, Kreczy A, Bartunek R, Darwiche K, Freitag L, Li Q, Huang H, Vogl T, LePilvert P, Tsiouda T, Tsakiridis K, Zarogoulidis K, Brachmann J

Therapeutics and Clinical Risk Management 2014, 10:207-215

Published Date: 27 March 2014

Successful management of an inadvertent excessive treprostinil overdose

Hohenforst-Schmidt W, Hornig J, Friedel N, Zarogoulidis P, Zarogoulidis K, Brachmann J

Drug Design, Development and Therapy 2013, 7:161-165

Published Date: 21 March 2013

Resveratrol-procyanidin blend: nutraceutical and antiaging efficacy evaluated in a placebo-controlled, double-blind study

Buonocore D, Lazzeretti A, Tocabens P, Nobile V, Cestone E, Santin G, Bottone MG, Marzatico F

Clinical, Cosmetic and Investigational Dermatology 2012, 5:159-165

Published Date: 5 October 2012

Application of reticulated platelets to transfusion management during autologous stem cell transplantation

Parco S, Vascotto F

OncoTargets and Therapy 2012, 5:1-5

Published Date: 26 January 2012

Multi-access drug delivery network and stability

Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:1757-1764

Published Date: 23 August 2011

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Breast Cancer: Targets and Therapy 2011, 3:9-19

Published Date: 16 March 2011


Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 6 June 2008